Oppenheimer Starts Forma Therapeutics (FMTX) at Outperform
Oppenheimer analyst Mark Breidenbach initiates coverage on Forma Therapeutics (NASDAQ: FMTX) with a Outperform rating and a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)